---
document_datetime: 2023-09-21 17:54:23
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/quixidar-epar-procedural-steps-taken-authorisation_en.pdf
document_name: quixidar-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3634277
conversion_datetime: 2025-12-24 16:58:06.810198
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

•

Medicinal Product no longer authorised The applicant N.V.Organon submitted on 14 February 2001 an application for Marketing Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for Quixidar,  through  the  centralised  procedure.  After  agreement  by  the  CPMP  on  30  June  2000,  this medicinal product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993 as amended. The Rapporteur and Co-Rapporteur appointed by the CPMP were: Rapporteur: Dr Per Nilsson                                           Co-Rapporteur: Prof Silvio Garattini Scientific Advice: The  applicant  received  Scientific  Advice  from  the  CPMP  on  21-22  October  1997.  The  Scientific Advice pertained to part IV of the dossier. Licensing status: The product was not licensed in any country at the time of submission of the application. 2. Steps taken for the assessment of the product · The procedure started on 1 March 2001. · The Rapporteur's first Assessment Report was circulated to all CPMP members on 8 May 2001 (Annex 1). The Co-Rapporteur's first Assessment Report was circulated to all CPMP members on 10 May 2001 (Annex 2) · During the meeting on 26-28 June 2001 the CPMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 27 June 2001 (Annex 3). · The company submitted the responses to the CPMP consolidated List of Questions on 9 August 2001. · The  Rapporteur  and Co-Rapporteur  circulated the response Assessment  Report  on  the company's responses  to  the  List  of  Questions  to  all  CPMP  members  on  27  September  2001 (Annex 5) · During the CPMP meeting on 14 November 2001, outstanding issues were addressed by the applicant during a hearing before the CPMP. · During  the  meeting  on  11-13  December  2001  the  CPMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for granting a Marketing Authorisation to Quixidar on 13 December 2001 . The CPMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decision on 21 March 2002.